Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available clinical trials

  • ALISCA-Lung1: A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer

    Contact:

    [email protected]

    ALISCA-Lung1 is a clinical trial that is exploring whether an investigational medication called alisertib is effective in treating patients with pathologically confirmed extensive-stage small-cell lung cancer following progression on or after first-line treatment with platinum-based chemotherapy and immunotherapy.

    Who can participate?

    Eligible patients must be at least 18 years old and cannot have used an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting. There are additional inclusion and exclusion criteria. The investigator at the study center will determine if you meet all of the criteria.

    Learn more

*These trials are listed for a period of 3 months.